RxDoctor Payments Data

Amina Djozo

Family · Utica, NYNPI 1467193383

Payments from drug & device makers

$1,497in general payments, 2019–2025

Across 58 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$725
  • Otsuka America Pharmaceutical, Inc.$352
  • Agios Pharmaceuticals, Inc.$125
  • Teva Pharmaceuticals USA, Inc.$105
  • Acadia Pharmaceuticals Inc$76
  • UCB, Inc.$62
  • plus $53 from 2 others

What the payments were for

  • Food & beverage$1,497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,497 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$245,250
Medicare patients
270
Services billed
3,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate18$44,663
EliquisApixaban148$43,863
SantylCollagenase Clostridium Hist.64$30,803
VeltassaPatiromer Calcium Sorbitex19$23,479
OzempicSemaglutide20$20,741
LinzessLinaclotide34$19,733
AbrysvoRsv Vacc, Pref A And Pref B/Pf36$11,326
XareltoRivaroxaban36$9,732
NuedextaDextromethorphan Hbr/Quinidine11$9,143
Humalog Kwikpen U-100Insulin Lispro42$7,348
Dabigatran EtexilateDabigatran Etexilate Mesylate47$6,708
Oseltamivir Phosphate100$6,179
Breo ElliptaFluticasone/Vilanterol14$6,131
Divalproex Sodium108$4,630
JardianceEmpagliflozin12$3,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$76$44,66318 claims
Smith+NephewSantyl$34$30,80364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →